CN112143693A - 一种生产病毒的方法及收获液组合物 - Google Patents
一种生产病毒的方法及收获液组合物 Download PDFInfo
- Publication number
- CN112143693A CN112143693A CN201910574886.3A CN201910574886A CN112143693A CN 112143693 A CN112143693 A CN 112143693A CN 201910574886 A CN201910574886 A CN 201910574886A CN 112143693 A CN112143693 A CN 112143693A
- Authority
- CN
- China
- Prior art keywords
- virus
- harvest
- cells
- composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 213
- 238000003306 harvesting Methods 0.000 title claims abstract description 166
- 239000000203 mixture Substances 0.000 title claims abstract description 117
- 238000004519 manufacturing process Methods 0.000 title abstract description 29
- 210000004027 cell Anatomy 0.000 claims abstract description 269
- 238000000034 method Methods 0.000 claims abstract description 61
- 239000007788 liquid Substances 0.000 claims abstract description 36
- 108010019160 Pancreatin Proteins 0.000 claims abstract description 31
- 229940055695 pancreatin Drugs 0.000 claims abstract description 31
- 238000012258 culturing Methods 0.000 claims abstract description 27
- 101710163270 Nuclease Proteins 0.000 claims abstract description 23
- 230000003612 virological effect Effects 0.000 claims abstract description 14
- 238000004806 packaging method and process Methods 0.000 claims abstract description 13
- 239000006174 pH buffer Substances 0.000 claims abstract description 12
- 210000004748 cultured cell Anatomy 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 81
- 241000700618 Vaccinia virus Species 0.000 claims description 35
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 26
- 239000000872 buffer Substances 0.000 claims description 25
- 241000700584 Simplexvirus Species 0.000 claims description 18
- 241000701161 unidentified adenovirus Species 0.000 claims description 18
- 241000713666 Lentivirus Species 0.000 claims description 17
- 241000991587 Enterovirus C Species 0.000 claims description 15
- 241001430294 unidentified retrovirus Species 0.000 claims description 15
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 12
- 241000702421 Dependoparvovirus Species 0.000 claims description 9
- 241000709661 Enterovirus Species 0.000 claims description 9
- 210000003501 vero cell Anatomy 0.000 claims description 9
- 241000712079 Measles morbillivirus Species 0.000 claims description 8
- 241000702263 Reovirus sp. Species 0.000 claims description 8
- 241000710961 Semliki Forest virus Species 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 241000709687 Coxsackievirus Species 0.000 claims description 7
- 238000004114 suspension culture Methods 0.000 claims description 7
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 6
- 241001529459 Enterovirus A71 Species 0.000 claims description 6
- 241000709721 Hepatovirus A Species 0.000 claims description 6
- 241000702670 Rotavirus Species 0.000 claims description 6
- 241000837158 Senecavirus A Species 0.000 claims description 6
- 238000004115 adherent culture Methods 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 239000002245 particle Substances 0.000 abstract description 10
- 230000003321 amplification Effects 0.000 abstract description 8
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 8
- 230000004071 biological effect Effects 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 description 54
- 239000006228 supernatant Substances 0.000 description 36
- 230000006037 cell lysis Effects 0.000 description 31
- 230000000694 effects Effects 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000003834 intracellular effect Effects 0.000 description 13
- 230000009089 cytolysis Effects 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 230000000174 oncolytic effect Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000011065 in-situ storage Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 238000010257 thawing Methods 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000003837 chick embryo Anatomy 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 244000309459 oncolytic virus Species 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 241000709691 Enterovirus E Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 241001372913 Maraba virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 101000760175 Homo sapiens Zinc finger protein 35 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100024672 Zinc finger protein 35 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011276 addition treatment Methods 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000012789 harvest method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940045426 kymriah Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16751—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910574886.3A CN112143693A (zh) | 2019-06-28 | 2019-06-28 | 一种生产病毒的方法及收获液组合物 |
| TW109121652A TW202115247A (zh) | 2019-06-28 | 2020-06-24 | 一種生產病毒的方法及收穫液組合物 |
| CN202080036017.6A CN113874495A (zh) | 2019-06-28 | 2020-06-24 | 一种生产病毒的方法及收获液组合物 |
| US17/596,732 US20220267713A1 (en) | 2019-06-28 | 2020-06-24 | Method for producing virus and harvest liquid composition |
| PCT/CN2020/097901 WO2020259532A1 (fr) | 2019-06-28 | 2020-06-24 | Procédé de production de virus et composition liquide de récolte |
| EP20832620.7A EP3992282A4 (fr) | 2019-06-28 | 2020-06-24 | Procédé de production de virus et composition liquide de récolte |
| JP2021576078A JP2022539511A (ja) | 2019-06-28 | 2020-06-24 | ウイルスの生産方法及び採取用溶液組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910574886.3A CN112143693A (zh) | 2019-06-28 | 2019-06-28 | 一种生产病毒的方法及收获液组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112143693A true CN112143693A (zh) | 2020-12-29 |
Family
ID=73869346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910574886.3A Pending CN112143693A (zh) | 2019-06-28 | 2019-06-28 | 一种生产病毒的方法及收获液组合物 |
| CN202080036017.6A Pending CN113874495A (zh) | 2019-06-28 | 2020-06-24 | 一种生产病毒的方法及收获液组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080036017.6A Pending CN113874495A (zh) | 2019-06-28 | 2020-06-24 | 一种生产病毒的方法及收获液组合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220267713A1 (fr) |
| EP (1) | EP3992282A4 (fr) |
| JP (1) | JP2022539511A (fr) |
| CN (2) | CN112143693A (fr) |
| TW (1) | TW202115247A (fr) |
| WO (1) | WO2020259532A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113373120A (zh) * | 2021-06-18 | 2021-09-10 | 浙江康佰裕生物科技有限公司 | Gmp级逆转录病毒载体的纯化方法与应用 |
| CN115261341A (zh) * | 2022-09-05 | 2022-11-01 | 东曜药业有限公司 | 一种澄清溶瘤痘苗病毒收获液的方法 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999007852A1 (fr) * | 1997-08-08 | 1999-02-18 | Commonwealth Scientific And Industrial Research Organisation | Vaccin contre le virus de la variole aviaire |
| CN1490050A (zh) * | 2002-10-17 | 2004-04-21 | 中国医学科学院医学生物学研究所 | 甲型肝炎灭活疫苗 |
| CN1582333A (zh) * | 2000-09-25 | 2005-02-16 | 波利门科学生物免疫研究有限公司 | 活疫苗及生产方法 |
| US20080138354A1 (en) * | 2006-07-21 | 2008-06-12 | City Of Hope | Cytomegalovirus vaccine |
| CN102257134A (zh) * | 2008-02-12 | 2011-11-23 | 赛诺菲巴斯德有限公司 | 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法 |
| CN103602639A (zh) * | 2013-08-16 | 2014-02-26 | 科兴（大连）疫苗技术有限公司 | 一种采用低渗透压收获液收获病毒的方法 |
| CN103614346A (zh) * | 2013-08-16 | 2014-03-05 | 科兴（大连）疫苗技术有限公司 | 一种采用高渗透压收获液收获病毒的方法 |
| US20190030188A1 (en) * | 2015-10-09 | 2019-01-31 | Universidad De Chile | Method for genetic treatment using the aav-xbp1s/gfp virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6830917B2 (en) * | 2001-12-10 | 2004-12-14 | Baxter Healthcare S.A. | Method of isolation and purification of trypsin from pronase protease and use thereof |
| RU2547587C2 (ru) * | 2008-09-24 | 2015-04-10 | Медиммун, Ллк | Способы культивирования клеток, размножения и очистки вирусов |
| CN102191225A (zh) * | 2010-03-17 | 2011-09-21 | 李福胜 | 一种用mdck细胞获得流感病毒高产毒株的方法 |
| AU2011281982B2 (en) * | 2010-07-20 | 2015-12-17 | Bavarian Nordic A/S | Method for harvesting expression products |
| WO2016201224A1 (fr) * | 2015-06-10 | 2016-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Procédés de production et de purification de compositions contenant des acides nucléiques |
| CN109554353B (zh) | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
-
2019
- 2019-06-28 CN CN201910574886.3A patent/CN112143693A/zh active Pending
-
2020
- 2020-06-24 EP EP20832620.7A patent/EP3992282A4/fr active Pending
- 2020-06-24 TW TW109121652A patent/TW202115247A/zh unknown
- 2020-06-24 CN CN202080036017.6A patent/CN113874495A/zh active Pending
- 2020-06-24 WO PCT/CN2020/097901 patent/WO2020259532A1/fr active Application Filing
- 2020-06-24 JP JP2021576078A patent/JP2022539511A/ja active Pending
- 2020-06-24 US US17/596,732 patent/US20220267713A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999007852A1 (fr) * | 1997-08-08 | 1999-02-18 | Commonwealth Scientific And Industrial Research Organisation | Vaccin contre le virus de la variole aviaire |
| CN1582333A (zh) * | 2000-09-25 | 2005-02-16 | 波利门科学生物免疫研究有限公司 | 活疫苗及生产方法 |
| CN1490050A (zh) * | 2002-10-17 | 2004-04-21 | 中国医学科学院医学生物学研究所 | 甲型肝炎灭活疫苗 |
| US20080138354A1 (en) * | 2006-07-21 | 2008-06-12 | City Of Hope | Cytomegalovirus vaccine |
| CN102257134A (zh) * | 2008-02-12 | 2011-11-23 | 赛诺菲巴斯德有限公司 | 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法 |
| CN103602639A (zh) * | 2013-08-16 | 2014-02-26 | 科兴（大连）疫苗技术有限公司 | 一种采用低渗透压收获液收获病毒的方法 |
| CN103614346A (zh) * | 2013-08-16 | 2014-03-05 | 科兴（大连）疫苗技术有限公司 | 一种采用高渗透压收获液收获病毒的方法 |
| US20190030188A1 (en) * | 2015-10-09 | 2019-01-31 | Universidad De Chile | Method for genetic treatment using the aav-xbp1s/gfp virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis |
Non-Patent Citations (3)
| Title |
|---|
| "疫苗", 生物技术通报, 31 December 1993 (1993-12-31), pages 40 - 42 * |
| 汪垣等: "带有乙型肝炎表面抗原基因的重组痘苗病毒 ——一种可能的乙型肝炎活疫苗", 中国科学B辑, no. 6, 30 June 1986 (1986-06-30), pages 623 - 634 * |
| 程世鹏等: "特种经济动物常用数据手册", 31 October 2000, 辽宁科学技术出版社, pages: 241 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113373120A (zh) * | 2021-06-18 | 2021-09-10 | 浙江康佰裕生物科技有限公司 | Gmp级逆转录病毒载体的纯化方法与应用 |
| CN115261341A (zh) * | 2022-09-05 | 2022-11-01 | 东曜药业有限公司 | 一种澄清溶瘤痘苗病毒收获液的方法 |
| CN115261341B (zh) * | 2022-09-05 | 2024-03-22 | 东曜药业有限公司 | 一种澄清溶瘤痘苗病毒收获液的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020259532A1 (fr) | 2020-12-30 |
| EP3992282A1 (fr) | 2022-05-04 |
| JP2022539511A (ja) | 2022-09-12 |
| EP3992282A4 (fr) | 2023-08-16 |
| TW202115247A (zh) | 2021-04-16 |
| CN113874495A (zh) | 2021-12-31 |
| US20220267713A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2489486C2 (ru) | Процесс получения поксвирусов и композиции поксвирусов | |
| KR102022952B1 (ko) | 백시니아 바이러스의 생산을 위한 방법 및 조성물 | |
| JP4024830B2 (ja) | Ｈｈｖ−７由来の組換ウイルスベクター、その製造方法、それを用いた宿主細胞の形質転換方法、それにより形質転換された宿主細胞およびそれを用いた遺伝子治療方法 | |
| CN105567618B (zh) | Hsv1-h129-bac及其变体的构建方法与应用 | |
| CN107267469B (zh) | 纤毛蛋白嵌合型重组人b型腺病毒及其制备方法 | |
| CN107002048A (zh) | 包含外源抗原的人巨细胞病毒 | |
| US10851350B1 (en) | Bioreactor production of virus from adherent cells | |
| CN110218706B (zh) | 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用 | |
| CN113874495A (zh) | 一种生产病毒的方法及收获液组合物 | |
| Naegele et al. | Viruses and renal carcinoma of Rana pipiens: XI. Isolation of frog virus 3 temperature-sensitive mutants; Complementation and genetic recombination | |
| CN112458064A (zh) | 盖他病毒全长感染性克隆、复制子系统及其制备和应用 | |
| CN101418314A (zh) | 山羊痘疫苗株表达载体 | |
| Chen et al. | Construction of a full-length infectious bacterial artificial chromosome clone of duck enteritis virus vaccine strain | |
| EP2460878B1 (fr) | Virus de la varicelle présentant un gène orf7 déficient, vaccin comprenant ce virus et utilisation de celui-ci | |
| CN111041001B (zh) | 治疗kras突变型肿瘤的安全型柯萨奇病毒及其药物组合物 | |
| WO2022071966A1 (fr) | Production de virus à partir de cellules adhérentes dans un bioréacteur | |
| RU2443779C2 (ru) | Способ получения препарата рекомбинантного аденовируса, характеризующегося сниженным коэффициентом соотношения физических и инфекционных вирусных частиц, и генно-терапевтический лекарственный препарат, полученный таким способом | |
| CN110564700B (zh) | 携带鲎凝集素基因的溶瘤痘苗病毒、构建方法及应用 | |
| JP7227654B2 (ja) | 固形癌及び微生物感染を治療するための方法及び組成物 | |
| WO2021197506A1 (fr) | Virus recombinant de la maladie de newcastle et procédé de préparation, plasmide recombinant, et utilisation associée | |
| CN104357460A (zh) | 重组鸭病毒性肠炎病毒、制备方法和应用 | |
| CN111690688B (zh) | 表达靶向REV的CRISPR/Cas9的重组马立克氏病病毒及其应用 | |
| WO2021197507A1 (fr) | Virus recombinant de la maladie de newcastle et procédé de préparation, plasmide recombinant, et utilisation associée | |
| WO2021212892A1 (fr) | Médicament antiviral à large spectre et son utilisation | |
| CN111979204B (zh) | 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40041438 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |